TLR9 antibody (AA 100-290) (FITC)

Catalog No. ABIN5564254

Product Details anti-TLR9 Antibody (FITC)

Target: TLR9 (Toll-Like Receptor 9 (TLR9))

Binding Specificity: AA 100-290

Reactivity: Human, Mouse

Host: Mouse

Clonality: Monoclonal

Conjugate: This TLR9 antibody is conjugated to FITC

Application: Flow Cytometry (FACS)

Specificity: Recognizes human and mouse TLR9.

Cross-Reactivity: Human, Mouse (Murine)

Purification: Protein G purified.

Immunogen: Recombinant human TLR9 protein (aa 100-290).

Clone: ABM1C51

Isotype: IgG1

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: In 10 mM TRIS containing 150 mM NaCl and 0.05 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: +4°C
Stable for at least 6 months after receipt when stored at +4°C.

Expiry Date: 6 months

Target Details for TLR9

Target: TLR9 (Toll-Like Receptor 9 (TLR9))

Alternative Name: TLR9 (TLR9 Products)

Synonyms: CD289 antibody, toll like receptor 9 antibody, toll-like receptor 9 antibody, TLR9 antibody, Tlr9 antibody

Background: TLR9 (Toll-like Receptor 9) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 is expressed by numerous cells of the immune system such as B lymphocytes, monocytes, natural killer (NK) cells and plasmacytoid dendritic cells. It is expressed intracellularly, within the endosomal compartments and functions to alert the immune system of viral and bacterial infections by binding to DNA rich in CpG motifs. This nucleotide-sensing TLR is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (also called oligodinucleotides, ODNs), and consequently signals via MYD88 and TRAF6, leading to NF-kappaB activation, cytokine secretion and the inflammatory response and eventually activation of a Th1-biased adaptive immune attack. Specific TLR9 agonists have been shown to have substantial antitumor activity, making the TLR9 signaling pathway an interesting target for therapeutic research.

Pathways: TLR Signaling, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades